Characterization of a KLK2-FGFR2 fusion gene in two cases of metastatic prostate cancer.

ABSTRACT:

Background

The fibroblast growth factor receptor (FGFR) signaling pathway is activated in multiple tumor types through gene amplifications, single base substitutions, or gene fusions. Multiple small molecule kinase inhibitors targeting FGFR are currently being evaluated in clinical trials for patients with FGFR chromosomal translocations. Patients with novel gene fusions involving FGFR may represent candidates for kinase inhibitors.

Methods

A targeted RNA-sequencing assay identified a KLK2-FGFR2 fusion gene in two patients with metastatic prostate cancer. NIH3T3 cells were transduced to express the KLK2-FGFR2 fusion. Migration assays, Western blots, and drug sensitivity assays were performed to functionally characterize the fusion.

Results

Expression of the KLK2-FGFR2

SUBMITTER: Krook MA 

PROVIDER: S-EPMC6824932 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature